Drugs that contain Oxycodone Hydrochloride

1. List of Oxaydo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8409616 ZYLA Extended release opioid abuse deterrent compositions and methods of making same
Nov, 2023

(9 months from now)

US7510726 ZYLA Methods and compositions for deterring abuse of opioid containing dosage forms
Nov, 2023

(9 months from now)

US7981439 ZYLA Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof
Nov, 2023

(9 months from now)

US8637540 ZYLA Compositions for deterring abuse of opioid containing dosage forms
Nov, 2023

(9 months from now)

US9492443 ZYLA Abuse deterrent compositions and methods of making same
May, 2024

(1 year, 3 months from now)

US7201920 ZYLA Methods and compositions for deterring abuse of opioid containing dosage forms
Mar, 2025

(2 years from now)

Market Authorisation Date: 17 June, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of OXAYDO before it's patent expiration?
More Information on Dosage

2. List of Oxycontin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

US10696684 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

US10407434 PURDUE PHARMA LP Process for preparing oxycodone compositions
Mar, 2025

(2 years from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675610 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US10369109 PURDUE PHARMA LP Abuse-proofed dosage form
Jun, 2023

(4 months from now)

US10675278 PURDUE PHARMA LP Crush resistant delayed-release dosage forms
Nov, 2023

(9 months from now)

US8309060 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US10130591 PURDUE PHARMA LP Abuse-proofed dosage form
Nov, 2023

(9 months from now)

US11304908 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9775808 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US8894988 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US8808741 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US11304909 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492392 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US9492393 PURDUE PHARMA LP Tamper resistant dosage forms
Aug, 2027

(4 years from now)

US8894987 PURDUE PHARMA LP Tamper resistant dosage forms
Mar, 2030

(7 years from now)

Market Authorisation Date: 05 April, 2010

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

3. List of Roxybond drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10314788 PROTEGA PHARMS Pharmaceutical compositions configured to deter dosage form splitting
Aug, 2028

(5 years from now)

US7955619 PROTEGA PHARMS Abuse resistant drugs, method of use and method of making
Aug, 2028

(5 years from now)

Market Authorisation Date: 20 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic